Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 / G蛋白偶联受体/G蛋白 / P2Y受体 / Ticagrelor/替卡格雷

Ticagrelor/替卡格雷 {[allProObj[0].p_purity_real_show]}

货号：A543807 同义名： 替格瑞洛 / AZD6140; AR-C 126532XX

Ticagrelor is a reversibly and oral active P2Y12 receptor antagonist with Ki of 2 nM, also inhibits CYP2C9 and midazolam 4-hydroxylation with IC50 of 10.5 μM and 8.2 μM respectively.

Ticagrelor/替卡格雷 化学结构 CAS号：274693-27-5
Ticagrelor/替卡格雷 化学结构
CAS号：274693-27-5
Ticagrelor/替卡格雷 3D分子结构
CAS号：274693-27-5
Ticagrelor/替卡格雷 化学结构 CAS号：274693-27-5
Ticagrelor/替卡格雷 3D分子结构 CAS号：274693-27-5
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Ticagrelor/替卡格雷 纯度/质量文件 产品仅供科研

货号：A543807 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

更多 >

Ticagrelor/替卡格雷 生物活性

靶点

  • P2Y receptor

    P2Y12, Ki:2 nM

  • P2Y receptor

    P2Y12, Ki:2 nM

  • P2Y receptor

    P2Y12, Ki:2 nM
描述 P2Y(12) plays an important role in regulating platelet aggregation and function. This receptor is the primary target of thienopyridine antiplatelet agents, the active metabolites of which bind irreversibly to the receptor, and of newer agents that can directly and reversibly modulate receptor activity[7]. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation, with a Ki value of 2 nM[7]. Ticagrelor moderately inhibited CYP2C9 activity in human liver microbodies, while it had almost no inhibitory activity for CYP1A2, CYP2B6, CYP2C8, CYP2C19, CYP2D6, and CYP2E1. In human liver microsomes, ticagrelor inhibited 4-hydroxylation of midazolam and activated 1-hydroxylation of midazolam. It was assessed in fresh human hepatocytes that ticagrelor was not an inducer of CYP1A2 or CYP3A4[8]. B16-F10 cells exhibited decreased interaction with platelets from ticagrelor-treated mice compared to saline-treated mice[9]. In B16-F10 melanoma intravenous and intrasplenic metastasis models, mice treated with a clinical dose of ticagrelor (10 mg/kg) exhibited marked reductions in lung (84%) and liver (86%) metastases. Furthermore, ticagrelor treatment improved survival compared to saline-treated animals. A similar effect was observed in a 4T1 breast cancer model, with reductions in lung (55%) and bone marrow (87%) metastases following ticagrelor treatment[9]. Single oral administration of ticagrelor (1-10 mg/kg) caused dose-related inhibitory effect on platelet aggregation. Ticagrelor, at the highest dose (10 mg/kg) significantly inhibited platelet aggregation at 1h after dosing and the peak inhibition was observed at 4h after dosing[10].

Ticagrelor/替卡格雷 动物研究

Dose Rat: 10 mg/kg - 30 mg/kg[3] (i.p.); 1 mg/kg - 30 mg/kg[4] (p.o.) Mice: 3 mg/kg[5] (p.o.)
Administration i.p., p.o.
Pharmacokinetics
Animal Rats[6]
Dose 10 mg/kg
Administration p.o.
AUC0→24h 1431.30 ng·h/ml
T1/2 2.94 h
Tmax 1.40 h
Cmax 296.53 ng/ml
AUC0→∞ 1479.91 ng·h/ml

Ticagrelor/替卡格雷 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02482298 - Completed - -
NCT02482298 Sickle Cell Disease Phase 2 Completed - United States, Florida ... 展开 >> Research Site Miami, Florida, United States, 33136 United States, Maryland Research Site Bethesda, Maryland, United States, 20817 United States, South Carolina Research Site Charleston, South Carolina, United States, 29425 Egypt Research Site Alexandria, Egypt, 21131 Research Site Cairo, Egypt, 11566 Research Site Cairo, Egypt France Research Site Bordeaux Cedex, France, 33076 Research Site Strasbourg, France, 67091 Italy Research Site Verona, Italy, 37134 Kenya Research Site Kisian, Kenya, 40100 Research Site Kisumu, Kenya, 40100 Research Site Nairobi, Kenya, 00100 Lebanon Research Site Beirut, Lebanon, 1107 2020 Research Site Beirut, Lebanon, 113-6044 Turkey Research Site Adana, Turkey, 01130 Research Site Mersin, Turkey, 33079 Research Site Van, Turkey, 65080 United Kingdom Research Site Harrow, United Kingdom, HA1 3UJ Research Site London, United Kingdom, E1 1BB Research Site London, United Kingdom, E9 6SR 收起 <<
NCT03129867 - Not yet recruiting December 31, 2019 -

Ticagrelor/替卡格雷 参考文献

[1]Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010 May;66(5):487-96.

[2]VAN Giezen JJ, Nilsson L, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009 Sep;7(9):1556-65.

[3]Ye Y, Birnbaum GD, et al. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol. 2015 Aug;35(8):1805-14.

[4]Sugidachi A, Ohno K, et al. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol. 2013 May;169(1):82-9.

[5]Lancellotti P, Musumeci L, et al. Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria. JAMA Cardiol. 2019 Jun 1;4(6):596-599.

[6]Na YG, Byeon JJ, et al. Pharmacokinetic/Pharmacodynamic Modeling To Predict the Antiplatelet Effect of the Ticagrelor-Loaded Self-Microemulsifying Drug Delivery System in Rats. Mol Pharm. 2020 Feb 24.

[7]VAN Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, Greasley PJ. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009 Sep;7(9):1556-65. doi: 10.1111/j.1538-7836.2009.03527.x. Epub 2009 Jun 23. PMID: 19552634.

[8]Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011 Apr;39(4):703-10. doi: 10.1124/dmd.110.037143. Epub 2010 Dec 22. PMID: 21177984.

[9]Gebremeskel S, LeVatte T, Liwski RS, Johnston B, Bezuhly M. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015 Jan 1;136(1):234-40. doi: 10.1002/ijc.28947. Epub 2014 May 14. PMID: 24798403.

[10]Sugidachi A, Ohno K, Ogawa T, Jakubowski J, Hashimoto M, Tomizawa A. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol. 2013 May;169(1):82-9. doi: 10.1111/bph.12108. PMID: 23347039; PMCID: PMC3632240.

Ticagrelor/替卡格雷 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.91mL

0.38mL

0.19mL

9.57mL

1.91mL

0.96mL

19.14mL

3.83mL

1.91mL

Ticagrelor/替卡格雷 技术信息

CAS号274693-27-5
分子式C23H28F2N6O4S
分子量 522.57
SMILES Code O[C@H]1[C@@H](O)[C@H](N2N=NC3=C(N[C@H]4[C@H](C5=CC=C(F)C(F)=C5)C4)N=C(SCCC)N=C32)C[C@@H]1OCCO
MDL No. MFCD09954148
别名 替格瑞洛 ;AZD6140; AR-C 126532XX; Possia; Brilique
运输蓝冰
InChI Key OEKWJQXRCDYSHL-FNOIDJSQSA-N
Pubchem ID 9871419
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C
溶解方案 请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案一
方案二
动物实验配方

2% DMSO+30% PEG 300+5% Tween 80+water 10 mg/mL

Tags: Ticagrelor | AZD6140;AR-C 126532XX;Possia;Brilique | 替格瑞洛 | P2Y Receptor | AmBeed-信号通路专用抑制剂 | Ticagrelor/替卡格雷 纯度/质量文件 | Ticagrelor/替卡格雷 生物活性 | Ticagrelor/替卡格雷 动物研究 | Ticagrelor/替卡格雷 临床数据 | Ticagrelor/替卡格雷 参考文献 | Ticagrelor/替卡格雷 实验方案 | Ticagrelor/替卡格雷 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z